References
- Anestis A, Karamouzis MV, Dalagiorgou G, Papavassiliou AG (2015). Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat Rev, 41, 547-53. https://doi.org/10.1016/j.ctrv.2015.04.009
- Barton VN, D'Amato NC, Gordon MA, et al (2015). Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer, 6, 206-13. https://doi.org/10.1007/s12672-015-0232-3
- Bryan RM, Mercer RJ, Bennett RC, et al (1984). Androgen receptors in breast cancer. Cancer, 54, 2436-40. https://doi.org/10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO;2-H
- Choi JE, Kang SH, Lee SJ, Bae YK (2015). Androgen receptor expression predicts decreased survival in early stage triplenegative breast cancer. Ann Surg Oncol, 22, 82-9. https://doi.org/10.1245/s10434-014-3984-z
- Gucalp A, Traina TA (2010). Triple-negative breast cancer: role of the androgen receptor. Cancer J, 16, 62-5. https://doi.org/10.1097/PPO.0b013e3181ce4ae1
- He J, Peng R, Yuan Z, et al (2012). Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol, 29, 406-10. https://doi.org/10.1007/s12032-011-9832-0
- Hu R, Dawood S, Holmes MD, et al (2011). Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res, 17, 1867-74. https://doi.org/10.1158/1078-0432.CCR-10-2021
- Lehmann BD, Bauer JA, Chen X, et al (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 121, 2750-67. https://doi.org/10.1172/JCI45014
- Luo X, Shi YX, Li ZM, Jiang WQ (2010). Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer, 29, 585-90. https://doi.org/10.5732/cjc.009.10673
- McGhan LJ, McCullough AE, Protheroe CA, et al (2014). Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol, 21, 361-7. https://doi.org/10.1245/s10434-013-3260-7
- McNamara KM, Yoda T, Miki Y, et al (2015). Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer. Int J Biol Markers, 30, 184-9. https://doi.org/10.5301/jbm.5000132
- McNamara KM, Yoda T, Takagi K, et al (2013). Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol, 133, 66-76. https://doi.org/10.1016/j.jsbmb.2012.08.007
- Niemeier LA, Dabbs DJ, Beriwal S, et al (2010). Androgen receptor in breast cancer: expression in estrogen receptorpositive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol, 23, 205-12. https://doi.org/10.1038/modpathol.2009.159
- Ogawa Y, Hai E, Matsumoto K, et al (2008). Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol, 13, 431-5. https://doi.org/10.1007/s10147-008-0770-6
- Park S, Koo J, Park HS, et al (2010). Expression of androgen receptors in primary breast cancer. Ann Oncol, 21, 488-92. https://doi.org/10.1093/annonc/mdp510
- Payandeh M, Sadeghi M, Sadeghi E, Aeinfar M (2015). Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 16, 4863-7. https://doi.org/10.7314/APJCP.2015.16.12.4863
- Payandeh M, Sadeghi M, Sadeghi E, Madani SH (2016a). Expression of p53 breast cancer in kurdish women in the west of Iran: a reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev, 17, 1261-4. https://doi.org/10.7314/APJCP.2016.17.3.1261
- Payandeh M, Shahriari-Ahmadi A, Sadeghi M, Sadeghi E (2016b). Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status. Asian Pac J Cancer Prev, 17, 1015-8. https://doi.org/10.7314/APJCP.2016.17.3.1015
- Rakha EA, El-Sayed ME, Green AR, et al (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32. https://doi.org/10.1002/cncr.22381
- Shah PD, Gucalp A, Traina TA (2013). The role of the androgen receptor in triple-negative breast cancer. Womens Health (Lond Engl), 9, 351-60. https://doi.org/10.2217/whe.13.33
- Sullivan HC, Oprea-Ilies G, Adams AL, et al (2014). Triplenegative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. Appl Immunohistochem Mol Morphol, 22, 17-23. https://doi.org/10.1097/PAI.0b013e318281148e
- Yu Q, Niu Y, Liu N, et al (2011). Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol, 22, 1288-94. https://doi.org/10.1093/annonc/mdq586